ImmVue Therapeutics Inc.

TORONTO, A6 · Biotech · Private

Immuno-oncology therapeutics targeting cancer immune response

Claim this profile

Follows are private to you and power your alerts

Updated · immvue.com

Sector
Biotech
Headquarters
TORONTO, A6
Latest Form D
$154K, Mar 2024
Total capital
$154K
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$154K
1 Form D · last Mar 2024
31 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
0
2 pending

Capital timeline

2024FEDERAL ↑EQUITY ↓Cumulative $154K1st Form D$154K
2024FEDERAL ↑EQUITY ↓Cumulative $154K1st Form D$154K

Latest events

  • Private capital raisedForm D · SEC · 1st filing$154K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Founders and team

From SEC Form D filings
  • David MoonExecutive Officer, DirectorNamed in SEC Form D filings
  • Jayan John NagendranDirectorNamed in SEC Form D filings
  • Joon-Hyung John KimDirectorNamed in SEC Form D filings
  • Sandy DerExecutive Officer, DirectorNamed in SEC Form D filings

What it has protected

USPTO · 0 granted of 2
  • PendingItk-ph Domain Inhibitors And Their UsesUSPTOApplication 63640566
  • PendingTec Kinase Agonists And Their Use In Enhancing Lymphocyte ActivationUSPTOApplication 63640573
  • Combined Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
  • EvonetixSimilar federal contract value in Biotech · null in contracts
  • RQ BioSimilar federal contract value in Biotech · null in contracts
  • Cyana Therapeutics, LLCSimilar federal contract value in Biotech · null in contracts
  • Tonix Pharmaceuticals, Inc.Similar federal contract value in Biotech · null in contracts
  • PharmassetX Inc.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .